Turner, N. C., Im, S., Saura, C., Juric, D., Loibl, S., Kalinsky, K., Schmid, P., Loi, S., Thanopoulou, E., Shankar, N., Jin, Y., Stout, T. J., Clark, T. D., Song, C., Jhaveri, K. L. (2025). INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with
            <i>PIK3CA</i>
            -mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.1003